Batten Disease
Also known as: Neuronal Ceroid Lipofuscinoses (NCLs), Spielmeyer-Vogt Disease, Jansky-Bielschowsky Disease, Batten-Spielmeyer-Vogt Disease, Kufs Disease
Batten disease is a rare, fatal, autosomal recessive neurodegenerative disorder that begins in childhood. It is the general name for a group of disorders called neuronal ceroid lipofuscinoses (NCLs). In Batten disease, abnormal storage of fatty, granular substances (lipopigments) called ceroid lipofuscin accumulates in nerve cells (neurons) in the brain, as well as in other tissues, such as the eye. This accumulation leads to progressive neurological impairment, including seizures, vision loss, motor difficulties, cognitive decline, and premature death. Different forms of Batten disease are classified by the gene affected and the age of onset of symptoms.
Imagine your brain cells have tiny garbage trucks that aren't working right. Batten disease is when these garbage trucks get too full of junk, and it makes it hard for your brain to work. This can cause problems with seeing, moving, and thinking.
Signs & Symptoms
- Progressive vision loss
- Seizures
- Motor difficulties (ataxia, clumsiness)
- Cognitive decline
- Dementia
- Myoclonus
- Behavioral changes
- Speech difficulties
- Sleep disturbances
- Movement disorders (e.g., dystonia)
Treatment Options
Brineura (cerliponase alfa)
MODERATELY EFFECTIVE Approved 2017Seizure Medications (Antiepileptics)
SUPPORTIVEPhysical Therapy
SUPPORTIVEOccupational Therapy
SUPPORTIVESpeech Therapy
SUPPORTIVENutritional Support
SUPPORTIVEPalliative Care
SUPPORTIVEDiagnosis
- Enzyme assays (e.g., PPT1, TPP1)
- Genetic testing (DNA sequencing of known NCL genes)
- Brain MRI
- Electroencephalogram (EEG)
- Skin or tissue biopsy (to detect lipopigments)
- Eye exam (fundoscopy to look for retinal changes)
History
Batten disease was first described by Frederick Batten, a British pediatrician, in 1903. He identified a distinct form of progressive neurological deterioration in several children. Subsequent research led to the recognition of different genetic subtypes and the underlying biochemical defects.
Recent Breakthroughs
FDA Approves Brineura (cerliponase alfa) for CLN2 Disease
The FDA approved Brineura, the first enzyme replacement therapy for CLN2 disease, a specific form of Batten disease. This marked a significant advancement in the treatment of this previously untreatable condition.
Advancements in Gene Therapy for Batten Disease
Several gene therapy clinical trials are underway, showing promise in slowing disease progression in various forms of Batten disease. These trials aim to deliver functional copies of the mutated genes to affected cells.